title: Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703.
abstract: Single-stranded oligodeoxynucleotides (ODN), containing nonmethylated cytosine-guanine motifs (CpG ODN), are recognized by the innate immune system as "danger signals." CpG ODN are efficacious immunomodulators but require phosphorothioate (PT) or other backbone modifications for metabolic stability, which cause toxicities in mice and primates. We therefore designed a covalently closed DNA molecule (dSLIM(®)) where two single-stranded loops containing CG motifs are connected through a double-stranded stem in the absence of any nonnatural DNA component. The most promising immunomodulator, MGN1703, comprises two loops of 30 nucleotides containing three CG motifs each, and a connecting stem stem of 28 base pairs. MGN1703 stimulates cytokine secretion [interferon (IFN)-α, IFN-γ, interleukin (IL)-12, IL-6, and IL-2] and activates immune cells by increased expression of CD80, CD40, human leukocyte antigen (HLA)-DR and ICAM-1. Efficacy of immunomodulation strictly depends on the descriptive dumbbell shape and size of the molecule. Variations in stem length and loop size lead to reduced potency of the respective members of the dSLIM(®) class. In a representative mouse model, toxicities from injections of high amounts of a CpG ODN-PT and of MGN1703 were evaluated. The CpG ODN-PT group showed severe organ damage, whereas no such or other pathologies were found in the MGN1703 group. Oncological clinical trials of MGN1703 already confirmed our design.
authors.affiliation: 1Mologen AG, Berlin, Germany.
authors.forename: Manuel
authors.initials: M
authors.lastname: Schmidt
authors.affiliation: 2Foundation Institute Molecular Biology and Bioinformatics, Freie Universitaet, Berlin, Germany.
authors.forename: Nicole
authors.initials: N
authors.lastname: Hagner
authors.affiliation: 3Department of Animal Health and Anatomy, Universidad Autonoma de Barcelona, Barcelona, Spain.
authors.forename: Alberto
authors.initials: A
authors.lastname: Marco
authors.affiliation: 4Vivotecnia, Madrid, Spain.
authors.forename: Sven A
authors.initials: SA
authors.lastname: König-Merediz
authors.affiliation: 1Mologen AG, Berlin, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Schroff
authors.affiliation: 2Foundation Institute Molecular Biology and Bioinformatics, Freie Universitaet, Berlin, Germany.
authors.forename: Burghardt
authors.initials: B
authors.lastname: Wittig
mesh_terms: D000276:Adjuvants, Immunologic / Q000737:chemistry* / Q000494:pharmacology*; D000818:Animals; D002460:Cell Line; D004247:DNA / Q000737:chemistry* / Q000494:pharmacology*; D015195:Drug Design; D005260:Female; D006801:Humans; D051379:Mice; D051217:Toll-Like Receptor 9 / Q000819:agonists*
chemical_list: D000276:Adjuvants, Immunologic; C000597235:MGN1703; C495371:TLR9 protein, human; D051217:Toll-Like Receptor 9; D004247:DNA
references.citation: Clin Cancer Res. 2005 Aug 15;11(16):5993-6001
references.pmid: 16115944
references.citation: J Immunol. 2005 Sep 15;175(6):3569-76
references.pmid: 16148100
references.citation: Nat Rev Drug Discov. 2006 Jun;5(6):471-84
references.pmid: 16763660
references.citation: J Clin Invest. 2007 May;117(5):1184-94
references.pmid: 17476348
references.citation: Nat Immunol. 2007 Jul;8(7):772-9
references.pmid: 17572678
references.citation: Immunol Rev. 2007 Dec;220:60-81
references.pmid: 17979840
references.citation: Immunity. 2008 Mar;28(3):315-23
references.pmid: 18342006
references.citation: J Immunol. 2000 Feb 1;164(3):1617-24
references.pmid: 10640783
references.citation: Vaccine. 2000 Mar 6;18(17):1755-62
references.pmid: 10699323
references.citation: Biochim Biophys Acta. 1999 Dec 10;1489(1):69-84
references.pmid: 10806998
references.citation: J Clin Oncol. 2000 Oct 1;18(19):3331-8
references.pmid: 11013272
references.citation: Nature. 2000 Dec 7;408(6813):740-5
references.pmid: 11130078
references.citation: J Exp Med. 2000 Aug 21;192(4):595-600
references.pmid: 10952730
references.citation: J Immunol. 2002 Feb 15;168(4):1659-63
references.pmid: 11823494
references.citation: Annu Rev Immunol. 2002;20:709-60
references.pmid: 11861616
references.citation: Front Biosci. 2003 Jan 1;8:e115-27
references.pmid: 12456326
references.citation: Int Immunopharmacol. 2002 Nov;2(12):1657-66
references.pmid: 12469940
references.citation: Cell Mol Life Sci. 2003 Feb;60(2):422-9
references.pmid: 12678505
references.citation: Biochem Biophys Res Commun. 2003 Jul 11;306(4):948-53
references.pmid: 12821134
references.citation: Clin Exp Immunol. 2003 Aug;133(2):227-32
references.pmid: 12869028
references.citation: Infect Immun. 2003 Aug;71(8):4398-404
references.pmid: 12874318
references.citation: Curr Opin Investig Drugs. 2003 Jun;4(6):686-90
references.pmid: 12901226
references.citation: Clin Cancer Res. 2003 Aug 1;9(8):3142-9
references.pmid: 12912966
references.citation: Curr Opin Mol Ther. 2003 Oct;5(5):553-9
references.pmid: 14601526
references.citation: Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14303-8
references.pmid: 14610275
references.citation: Nat Immunol. 2004 Feb;5(2):190-8
references.pmid: 14716310
references.citation: Curr Oncol Rep. 2004 Mar;6(2):88-95
references.pmid: 14751085
references.citation: Nat Med. 2004 Feb;10(2):187-92
references.pmid: 14745443
references.citation: Nat Rev Immunol. 2004 Apr;4(4):249-58
references.pmid: 15057783
references.citation: Inflammation. 2004 Feb;28(1):39-51
references.pmid: 15072229
references.citation: Blood. 2004 May 1;103(9):3480-9
references.pmid: 14656881
references.citation: Eur J Immunol. 2004 Sep;34(9):2541-50
references.pmid: 15307186
references.citation: Nat Immunol. 2004 Oct;5(10):987-95
references.pmid: 15454922
references.citation: J Immunol. 2010 Jun 15;184(12):7092-9
references.pmid: 20483722
references.citation: J Clin Oncol. 2011 Jul 1;29(19):2667-74
references.pmid: 21632509
references.citation: Vaccine. 2011 Aug 5;29(34):5778-84
references.pmid: 21664398
references.citation: Ann Oncol. 2012 Jan;23(1):72-7
references.pmid: 21464154
references.citation: Nucleic Acid Ther. 2012 Apr;22(2):77-89
references.pmid: 22352814
references.citation: J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24
references.pmid: 24816725
references.citation: Eur J Cancer. 2015 Jan;51(2):146-56
references.pmid: 25480557
references.citation: Nat Immunol. 2010 May;11(5):373-84
references.pmid: 20404851
references.citation: J Cell Biol. 1983 Jan;96(1):1-27
references.pmid: 6298247
references.citation: Proc Natl Acad Sci U S A. 1986 Jun;83(12):4143-6
references.pmid: 3012555
references.citation: Biochemistry. 1987 Nov 3;26(22):7150-9
references.pmid: 3427065
references.citation: Nucleic Acids Res. 1988 Apr 25;16(8):3209-21
references.pmid: 2836790
references.citation: Nucleic Acids Res. 1991 Feb 25;19(4):747-50
references.pmid: 1850122
references.citation: Nucleic Acids Res. 1992 Nov 11;20(21):5857-8
references.pmid: 1454556
references.citation: Nucleic Acids Res. 1993 Jul 25;21(15):3405-11
references.pmid: 7688452
references.citation: J Biol Chem. 1994 Oct 28;269(43):26801-5
references.pmid: 7929417
references.citation: Nature. 1995 Apr 6;374(6522):546-9
references.pmid: 7700380
references.citation: Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2879-83
references.pmid: 8610135
references.citation: Antisense Nucleic Acid Drug Dev. 1996 Summer;6(2):133-9
references.pmid: 8843328
references.citation: Biochem Pharmacol. 1997 Apr 25;53(8):1123-32
references.pmid: 9175717
references.citation: Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):503-10
references.pmid: 9361909
references.citation: Blood. 1998 Jan 1;91(1):22-9
references.pmid: 9414265
references.citation: Antisense Nucleic Acid Drug Dev. 1997 Dec;7(6):575-84
references.pmid: 9450915
references.citation: Eur J Immunol. 1998 Jun;28(6):2045-54
references.pmid: 9645386
references.citation: Blood. 1998 Sep 1;92(5):1617-25
references.pmid: 9716589
references.citation: J Immunol. 1998 Sep 1;161(5):2428-34
references.pmid: 9725240
references.citation: J Immunol. 1998 Nov 1;161(9):4463-6
references.pmid: 9794366
references.citation: Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15553-8
references.pmid: 9861007
references.citation: J Immunol. 2005 Jan 15;174(2):605-8
references.pmid: 15634876